Calliditas Therapeutics
Maria Andersson has a robust background in finance and accounting, with experience managing financial systems and departments in various companies. Maria has held titles such as Finance System Manager, Finance Manager, Accounting Manager, and Redovisningschef. Maria has experience in a wide range of financial tasks, including bookkeeping, reconciliations, financial reporting, and team management. Maria has also been involved in system upgrades and process improvements. Maria's education includes a degree in Ekonomi and additional courses in Spanish language, grammar, commerce, and translation.
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.